Shots:

• The P-III (MOVe-OUT) trial evaluates the efficacy of molnupiravir (800mg, bid) vs PBO in non-hospitalized high-risk adults with COVID-19 who had one risk factor associated with poor disease outcomes. The therapy is being developed in collaboration with Ridgeback
• In all randomized analyses, 47.7% of patients had signs or symptoms. In an interim analysis (7.3% vs 4.1%) were hospitalized or died, 3.0% & 30% absolute & relative risk reduction, 50% relative reduction in the risk of hospitalization or death @29 Day
• Merck continues to discuss additional measures to expand global access to molnupiravir while regulatory applications are under review including applications for EUA by US FDA & MHLW

Ref: Businesswire | Image: Merck